Screen for early signs with the FIT Colon Cancer Test
STEP-1 (semaglutide 2.4 mg) and medication use In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs
doi: 10.1038/s41575-019-0144-8 189 LassaillyGCaiazzoRBuobDPigeyreMVerkindtHLabreucheJet al
The highest retatrutide dose produced the biggest number in the Phase 3 TRIUMPH-1 trial: an average body-weight reduction of 28.3% at 80 weeks
By Alyx Arnett A class of weight-loss medications is gaining attention for its potential to become a pharmacological treatment option for obstructive sleep apnea (OSA) in patients with obesity
Curr Diabetes Rev 19:3145 Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimers disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial